This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by De Nicolo, A. Articles by Caligo, M. A. PubMed PubMed Citation Articles by De Nicolo, A. Articles by Caligo, M. A. Related Collections Risk Assessment: Hereditary Cancer Syndromes/Cancer Genetics Risk Assessment

A Novel Breast Cancer–Associated BRIP1 (FANCJ/BACH1) Germ-line Mutation Impairs Protein Stability and Function

Authors' Affiliations: Departments of ¹ Cancer Biology, and ² Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; ³ Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts and ⁴ Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, Transplants and New Technologies in Medicine, Section of Oncogenetics, University of Pisa and University Hospital of Pisa, Pisa, Italy

Requests for reprints: Ronny Drapkin, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Room JFB 215D, Boston, MA 02115. Phone: 617-632-4380; Fax: 617-582-8761; E-mail: ronny_drapkin{at}dfci.harvard.edu.

Purpose: BRCA1-interacting protein 1 (BRIP1; FANCJ/BACH1), which encodes a DNA helicase that interacts with BRCA1, has been suggested to be a low-penetrance breast cancer predisposing gene. We aimed to assess whether BRIP1 mutations contribute to breast cancer susceptibility in our population and, if so, to investigate the effect of such mutation(s) on BRIP1 function.

Experimental Design: A series of 49 breast/ovarian cancer families, devoid of a BRCA1/BRCA2 mutation, were screened for BRIP1 mutations. Functional analyses, including coimmunoprecipitation and stability assays, were employed to further characterize a previously unreported variant.

Results: Five sequence alterations were identified, of which four had been already described. Herein, we report a novel BRIP1 germ-line mutation identified in a woman with early-onset breast cancer. The mutation consists of a 4-nucleotide deletion (c.2992-2995delAAGA) in BRIP1 exon 20 that causes a shift in the reading frame, disrupts the BRCA1-binding domain of BRIP1, and creates a premature stop codon. Functional analysis of the recombinant mutant protein in transfected cells showed that the truncation interferes with the stability of the protein and with its ability to interact with BRCA1. Loss of the wild-type BRIP1 allele with retention of the mutated one was observed in the patient's breast tumor tissue.

Conclusions: These results, by showing that the newly identified BRIP1 c.2992-2995delAAGA mutation is associated with instability and functional impairment of the encoded protein, provide further evidence of a breast cancer–related role for BRIP1.